Cited 0 times in
Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김형일 | - |
dc.date.accessioned | 2021-09-29T00:25:01Z | - |
dc.date.available | 2021-09-29T00:25:01Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2093-582X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183820 | - |
dc.description.abstract | Purpose: To compare long-term disease-free survival (DFS) between patients receiving tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX) adjuvant chemotherapy (AC) for gastric cancer (GC). Materials and methods: This retrospective multicenter observational study enrolled 983 patients who underwent curative gastrectomy with consecutive AC with S-1 or CAPOX for stage II or III GC at 27 hospitals in Korea between February 2012 and December 2013. We conducted propensity score matching to reduce selection bias. Long-term oncologic outcomes, including DFS rate over 5 years (over-5yr DFS), were analyzed postoperatively. Results: The median and longest follow-up period were 59.0 and 87.6 months, respectively. DFS rate did not differ between patients who received S-1 and CAPOX for pathologic stage II (P=0.677) and stage III (P=0.899) GC. Moreover, hazard ratio (HR) for recurrence did not differ significantly between S-1 and CAPOX (reference) in stage II (HR, 1.846; 95% confidence interval [CI], 0.693-4.919; P=0.220) and stage III (HR, 0.942; 95% CI, 0.664-1.337; P=0.738) GC. After adjustment for significance in multivariate analysis, pT (4 vs. 1) (HR, 11.667; 95% CI, 1.595-85.351; P=0.016), pN stage (0 vs. 3) (HR, 2.788; 95% CI, 1.502-5.174; P=0.001), and completion of planned chemotherapy (HR, 2.213; 95% CI, 1.618-3.028; P<0.001) were determined as independent prognostic factors for DFS. Conclusions: S-1 and CAPOX AC regimens did not show significant difference in over-5yr DFS after curative gastrectomy in patients with stage II or III GC. The pT, pN stage, and completion of planned chemotherapy were prognostic factors for GC recurrence. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Gastric Cancer Association | - |
dc.relation.isPartOf | JOURNAL OF GASTRIC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Chang Min Lee | - |
dc.contributor.googleauthor | Moon-Won Yoo | - |
dc.contributor.googleauthor | Young-Gil Son | - |
dc.contributor.googleauthor | Sung Jin Oh | - |
dc.contributor.googleauthor | Jong-Han Kim | - |
dc.contributor.googleauthor | Hyoung-Il Kim | - |
dc.contributor.googleauthor | Joong-Min Park | - |
dc.contributor.googleauthor | Hoon Hur | - |
dc.contributor.googleauthor | Ye Seob Jee | - |
dc.contributor.googleauthor | Sun-Hwi Hwang | - |
dc.contributor.googleauthor | Sung-Ho Jin | - |
dc.contributor.googleauthor | Sang Eok Lee | - |
dc.contributor.googleauthor | Ji-Ho Park | - |
dc.contributor.googleauthor | Kyung Won Seo | - |
dc.contributor.googleauthor | Sungsoo Park | - |
dc.contributor.googleauthor | Chang Hyun Kim | - |
dc.contributor.googleauthor | In Ho Jeong | - |
dc.contributor.googleauthor | Han Hong Lee | - |
dc.contributor.googleauthor | Sung Il Choi | - |
dc.contributor.googleauthor | Sang-Il Lee | - |
dc.contributor.googleauthor | Chan Young Kim | - |
dc.contributor.googleauthor | In-Hwan Kim | - |
dc.contributor.googleauthor | Myoung-Won Son | - |
dc.contributor.googleauthor | Kyung Ho Pak | - |
dc.contributor.googleauthor | Sungsoo Kim | - |
dc.contributor.googleauthor | Moon-Soo Lee | - |
dc.contributor.googleauthor | Jae-Seok Min | - |
dc.identifier.doi | 10.5230/jgc.2020.20.e13 | - |
dc.contributor.localId | A01154 | - |
dc.relation.journalcode | J01415 | - |
dc.identifier.eissn | 2093-5641 | - |
dc.identifier.pmid | 32595999 | - |
dc.subject.keyword | Adjuvant chemotherapy | - |
dc.subject.keyword | Disease-free survival | - |
dc.subject.keyword | Gastric cancer | - |
dc.contributor.alternativeName | Kim, Hyoung Il | - |
dc.contributor.affiliatedAuthor | 김형일 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 152 | - |
dc.citation.endPage | 164 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTRIC CANCER, Vol.20(2) : 152-164, 2020-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.